Furthermore, we demonstrated that pharmacological interventions targeting the UCP1/MMP/NLRP3 inflammasome–IL-1β axis are promising therapeutic strategies for the treatment of atherosclerosis in small- and large-animal models. The gene discussed is NLRP3; the disease is atherosclerosis.